Orforglipron to Dulaglutide Dose Conversion Guide
Medically reviewed by Veronica Hackethal | MD, MSc, Harvard University | University of Oxford | Columbia Vagelos College of Physicians and Surgeons on July 27th, 2026.
Published on July 25th, 2026. Updated on July 28th, 2026.
Key takeaways
No validated orforglipron to dulaglutide conversion ratio exists because orforglipron is not yet FDA-approved, making clinician guidance essential before any switch.
The two drugs differ fundamentally in route of administration, molecular structure, and half-life, so milligram-to-milligram comparisons are not clinically meaningful.
Standard clinical practice is to start dulaglutide at the lowest approved dose (0.75 mg weekly) and titrate based on tolerability and blood sugar response.
Patients should expect a possible reset of GI side effects and must monitor blood glucose more frequently during the first two to four weeks after switching.
A full medication review with a physician or pharmacist is critical before switching to avoid compounding hypoglycemia risk from insulin or sulfonylureas.
Understanding the Two Medications Before You Switch
Orforglipron and dulaglutide both activate the GLP-1 receptor, but they are fundamentally different types of drugs. Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist. Unlike the injectable GLP-1 medications most patients know, it is a non-peptide compound taken as a pill. As of early 2025, orforglipron remains in late-stage clinical development and has not received FDA approval.
Dulaglutide, sold under the brand name Trulicity, is an injectable GLP-1 receptor agonist given once weekly by subcutaneous injection. It is FDA-approved for the management of type 2 diabetes and for reducing cardiovascular risk in adults who have established heart disease or multiple cardiovascular risk factors. These structural and regulatory differences set the stage for why switching between the two requires careful clinical planning rather than a straightforward dose conversion.
Why People Search for a Conversion Guide
Several real-world scenarios prompt patients and clinicians to look for dosing guidance when moving from orforglipron to dulaglutide. Clinical trial participants who were enrolled in orforglipron studies may need a comparable injectable alternative once the study protocol ends. Formulary changes or insurance coverage decisions may also shift a patient toward an approved injectable before orforglipron becomes commercially available.
Physicians managing these transitions want to preserve the glycemic control and weight loss progress a patient may have built while on an orforglipron trial regimen. Understanding what a reasonable starting point looks like for dulaglutide, and what to watch for afterward, helps maintain momentum without introducing new risks.
Key Pharmacological Differences That Shape Dosing Decisions
Because the two drugs differ in nearly every pharmacological dimension, milligram-to-milligram comparisons carry no clinical meaning. The table below summarizes the most important distinctions.
Feature |
Orforglipron |
Dulaglutide (Trulicity) |
|---|---|---|
Route of administration |
Oral, once daily |
Subcutaneous injection, once weekly |
Molecular type |
Non-peptide small molecule |
Peptide-Fc fusion protein |
FDA approval status |
Not yet approved (as of early 2025) |
Approved for type 2 diabetes and CV risk reduction |
Available doses |
Investigational (trial-based) |
0.75 mg, 1.5 mg, 3 mg, 4.5 mg weekly |
Half-life |
Shorter, consistent with daily oral dosing |
Approximately 5 days |
Bioavailability considerations |
Oral absorption affected by food and GI factors |
Predictable subcutaneous absorption |
The difference in half-life is particularly important when planning the timing of a switch. Dulaglutide's longer half-life means it builds in the body gradually, so the gap between stopping orforglipron and starting the injection needs to be managed thoughtfully to avoid a period of inadequate glucose coverage.
How Clinicians Approach the Transition in Practice
Because no validated conversion formula exists, the standard clinical approach is to treat the switch as a new initiation of dulaglutide rather than a continuation of GLP-1 therapy at an equivalent dose. Most prescribers start patients at dulaglutide 0.75 mg once weekly, regardless of which GLP-1 agent they were previously taking or at what dose.
After four weeks at the starting dose, clinicians typically reassess tolerability and A1C trajectory before titrating to 1.5 mg. Higher doses of 3 mg and 4.5 mg are available for patients who need additional blood sugar control or weight loss benefit and are tolerating the lower doses well.
Timing matters. Because orforglipron is a once-daily oral agent, stopping it creates a relatively quick drop in drug exposure. Most clinicians suggest administering the first dulaglutide injection at the next logical weekly interval after the final orforglipron dose. This minimizes any glycemic gap while avoiding an overlap that could amplify GI side effects.
Monitoring Your Health After the Switch
The transition period between GLP-1 agents is a time when both patients and care teams need to stay alert. Blood glucose should be checked more frequently during the first two to four weeks after switching. Even patients whose diabetes was well-controlled on orforglipron may experience some variability as dulaglutide reaches steady-state concentrations.
GI side effects deserve special attention. Nausea, vomiting, and diarrhea are common with GLP-1 receptor agonists, and patients who tolerated orforglipron well should not assume they will have the same experience with a peptide-based injectable. The two drugs interact with GLP-1 receptors through different molecular mechanisms, and individual tolerability can shift.
Weight trajectory should also be tracked separately. Dulaglutide supports weight loss, but the degree of effect may differ from what a patient experienced during an orforglipron trial. If weight regain becomes a concern, discussing a dose increase or adjunct strategies with a clinician early can help prevent a significant setback.
What to Discuss With Your Care Team Before Making the Switch
A medication switch of this nature works best when it starts with a clear conversation. Begin by identifying the reason for the change. Whether the driver is cost, insurance formulary shifts, a clinical trial ending, or a perceived difference in efficacy, that reason shapes how urgently the transition needs to happen and what alternatives might be available.
Next, bring a complete list of all current medications to the review. Patients taking insulin or sulfonylureas alongside a GLP-1 agent carry a meaningful risk of hypoglycemia, and adding or changing a GLP-1 drug may require dose reductions in those companion medications. A pharmacist or physician needs to assess the full picture before the switch begins.
Finally, if the reason for switching is cost-related, ask specifically about patient assistance programs. Dulaglutide's manufacturer offers support programs that may significantly reduce out-of-pocket costs. Doctronic's 24/7 platform, which is HIPAA aligned and available at no cost for AI consultations, can also help patients explore their options and prepare informed questions before a prescriber visit.
Frequently Asked Questions
No official conversion ratio currently exists. Because orforglipron is not yet FDA-approved and has no finalized clinical dosing data, no validated formula translates its doses to dulaglutide equivalents. Clinicians rely on titration protocols and clinical judgment rather than a fixed conversion when making this switch.
Most clinicians recommend starting dulaglutide at the lowest approved dose of 0.75 mg once weekly, regardless of which GLP-1 agent the patient was previously taking. This approach allows for tolerability assessment and gradual titration upward to 1.5 mg, 3 mg, or 4.5 mg based on glycemic response and side effects.
Because orforglipron is taken daily, most clinicians suggest timing the first dulaglutide injection at the next scheduled weekly interval after the last orforglipron dose. This approach helps avoid a glycemic gap while minimizing overlap. Your prescriber may adjust this timing based on your individual situation and blood sugar levels.
Weight outcomes vary by individual. Dulaglutide does support weight loss, particularly at higher doses (3 mg and 4.5 mg weekly), but its effect may differ from what you experienced on orforglipron during a clinical trial. Tracking weight separately after the switch helps your care team determine whether dose adjustments are needed.
This switch should not be attempted without medical supervision. The two medications differ in structure, route, and pharmacokinetics. A clinician needs to review your full medication list, assess hypoglycemia risk from other diabetes drugs, and establish a monitoring plan. Attempting an unsupervised switch could lead to dangerous blood sugar swings.
The Bottom Line
Switching from orforglipron to dulaglutide is not as simple as plugging numbers into a conversion formula. Because orforglipron lacks FDA approval and validated clinical dosing benchmarks, no official conversion ratio exists. The two medications differ in molecular structure, route of administration, and half-life, making direct dose comparisons clinically meaningless. The recommended approach is to start dulaglutide at its lowest approved dose and titrate carefully while monitoring blood glucose and GI tolerability. Doctronic has already facilitated more than 22 million AI consultations, with 99.2% treatment plan alignment with board-certified physicians, and offers free AI consultations and affordable $39 video visits to help patients navigate complex medication decisions like this one. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.
Related articles
Get dulaglutide dosing guidance
Chat Now